BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar.
Author | Tang, Patrick |
Author | Hasan, Mohammad R |
Author | Chemaitelly, Hiam |
Author | Yassine, Hadi M |
Author | Benslimane, Fatiha M |
Author | Al Khatib, Hebah A |
Author | AlMukdad, Sawsan |
Author | Coyle, Peter |
Author | Ayoub, Houssein H |
Author | Al Kanaani, Zaina |
Author | Al Kuwari, Einas |
Author | Jeremijenko, Andrew |
Author | Kaleeckal, Anvar Hassan |
Author | Latif, Ali Nizar |
Author | Shaik, Riyazuddin Mohammad |
Author | Abdul Rahim, Hanan F |
Author | Nasrallah, Gheyath K |
Author | Al Kuwari, Mohamed Ghaith |
Author | Al Romaihi, Hamad Eid |
Author | Butt, Adeel A |
Author | Al-Thani, Mohamed H |
Author | Al Khal, Abdullatif |
Author | Bertollini, Roberto |
Author | Abu-Raddad, Laith J |
Available date | 2021-11-07T08:31:18Z |
Publication Date | 2021-11-02 |
Publication Name | Nature Medicine |
Identifier | http://dx.doi.org/10.1038/s41591-021-01583-4 |
Citation | Tang, P., Hasan, M.R., Chemaitelly, H. et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. Nat Med (2021). https://doi.org/10.1038/s41591-021-01583-4 |
ISSN | 1078-8956 |
Abstract | With the global expansion of the highly transmissible SARS-CoV-2 Delta (B.1.617.2) variant, we conducted a matched test-negative case-control study to assess the real-world effectiveness of COVID-19 messenger RNA vaccines against infection with Delta in Qatar's population. BNT162b2 effectiveness against any, symptomatic or asymptomatic, Delta infection was 45.3% (95% CI, 22.0-61.6%) ≥14 d after the first vaccine dose, but only 51.9% (95% CI, 47.0-56.4%) ≥14 d after the second dose, with 50% of fully vaccinated individuals receiving their second dose before 11 May 2021. Corresponding mRNA-1273 effectiveness ≥14 d after the first or second dose was 73.7% (95% CI, 58.1-83.5%) and 73.1% (95% CI, 67.5-77.8%), respectively. Notably, effectiveness against Delta-induced severe, critical or fatal disease was 93.4% (95% CI, 85.4-97.0%) for BNT162b2 and 96.1% (95% CI, 71.6-99.5%) for mRNA-1273 ≥ 14 d after the second dose. Our findings show robust effectiveness for both BNT162b2 and mRNA-1273 in preventing Delta hospitalization and death in Qatar's population, despite lower effectiveness in preventing infection, particularly for the BNT162b2 vaccine. |
Language | en |
Publisher | Nature Researc |
Subject | BNT162b2 mRNA-1273 COVID-19 vaccine |
Type | Article |
ESSN | 1546-170X |
Files in this item
This item appears in the following Collection(s)
-
Biomedical Research Center Research [709 items ]
-
Biomedical Sciences [692 items ]
-
COVID-19 Research [799 items ]
-
Mathematics, Statistics & Physics [722 items ]
-
Public Health [401 items ]